TY - JOUR
T1 - The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes
AU - Rajpathak, Swapnil N.
AU - Gunter, Marc J.
AU - Wylie-Rosett, Judith
AU - Ho, Gloria Y.F.
AU - Kaplan, Robert C.
AU - Muzumdar, Radhika
AU - Rohan, Thomas E.
AU - Strickler, Howard D.
PY - 2009
Y1 - 2009
N2 - This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic β-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.
AB - This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic β-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.
KW - Diabetes
KW - Glucose
KW - IGFBP
KW - Insulin-like growth factor (IGF)-I
UR - http://www.scopus.com/inward/record.url?scp=65549095726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65549095726&partnerID=8YFLogxK
U2 - 10.1002/dmrr.919
DO - 10.1002/dmrr.919
M3 - Review article
C2 - 19145587
AN - SCOPUS:65549095726
SN - 1520-7552
VL - 25
SP - 3
EP - 12
JO - Diabetes/Metabolism Research and Reviews
JF - Diabetes/Metabolism Research and Reviews
IS - 1
ER -